Pfizer and BioNTech received a larger initial order from the U.S. government than Moderna did for omicron boosters.
The U.S. is also paying a higher price per dose for the Pfizer-BioNTech booster than for Moderna's booster.
Moderna could still be the biggest winner, simply because it doesn't have to share its vaccine profits.

Search form

You are here